SHTG Digest — Friday May 15, 2026

A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.